Recent insider selling of Avanos Medical stock, particularly by Senior VP Michael Greiner, is concerning. Insiders' lack of significant ownership and their share selling could deter potential investors.
Unresolved challenges may be indicated by weak growth and share price performance. The market's focus is likely on revenue due to the company's lack of profits. Accelerated revenue growth or profits could attract more interest in the stock.
Analysts predict a below-average future growth rate for Avanos Medical despite its high P/E ratio. This warns of a possible risk for investors, who might pay a premium not supported by the earnings outlook.
Avanos Medical股票討論區
利潤表顯示近兩年盈利得益於營業費用的控制,主要是其它營業費用的減少。
2022年利息費用佔營業利潤的12%,負擔略高。
2023Q1營收下滑2.9%,營業利潤下滑70%至260萬,淨利潤略虧。
目前看盈利數據還很有限,可以繼續觀察。
暫無評論